Tiletamine HCl and zolazepam HCl are supplied as a fixed 1:1 w/w veterinary-grade API pair. In the downstream scenarios that follow, the material is handled as a sterile parenteral powder for reconstitution, injectable solution, or compounded low-volume syringe presentation. Tablet, capsule, and granule presentations are excluded from these scenarios because public regulatory monographs and published bioavailability data for oral administration of this dissociative-benzodiazepine pair are insufficient to support a licensed oral solid dosage form.

What Lyophilization Parameters Govern a 1:1 Tiletamine-Zolazepam Fixed-Ratio Injection?

In small animal veterinary practice, the terminal dosage form is a sterile lyophilized cake containing 250 mg tiletamine HCl and 250 mg zolazepam HCl per vial, reconstituted with 5 mL sterile water for injection to produce 100 mg/mL total active, equivalent to 50 mg/mL of each moiety. The downstream production process uses an aqueous bulk solution in which both salts are dissolved at a 1:1 mass ratio, pH-adjusted under controlled hold times, and sterile filtered through a 0.22 µm membrane before aseptic filling into 5 mL Type I borosilicate glass vials. Freeze-drying is performed in a chamber capable of stoppering under vacuum; product temperature thermocouples are placed in center and edge vials to control the primary drying shelf temperature below the collapse temperature of the formulation, because edge vials receive additional radiative energy from chamber walls and dry faster than center positions. Unloading and capping are carried out under pre-dried nitrogen or equivalent dry-air conditions, because the cake absorbs moisture rapidly and undergoes glassy collapse when exposed to ambient humidity. Residual moisture is measured by Karl Fischer titration and controlled to ≤1.0% w/w; vials exhibiting collapsed cake structure, partially detached stoppers, or reconstitution failures are rejected by automated visual inspection. Container closure integrity is confirmed by vacuum decay method, and elastomeric closure compatibility is evaluated according to USP 381 and Ph. Eur. 3.2.9. The applicable compliance framework includes USP 71 and Ph. Eur. 2.6.1 for sterility, USP 85 and Ph. Eur. 2.6.14 for bacterial endotoxins, 21 CFR 211.113 for microbiological control of the aseptic fill line, 21 CFR 211.165 for finished-product release testing, VICH GL3(R) for stability, and EU GMP Annex 1:2022 for sterile manufacturing design. Terminal finished product types are 5 mL multi-dose vials of lyophilized powder for solution for injection and the resulting 100 mg/mL solution prepared at the point of care.

The approved canine dose range is 6.0–12.0 mg/kg by intramuscular injection and the feline dose range is 9.7–11.9 mg/kg; these figures are product-label parameters, not compounding instructions. Production experience shows that batch-to-batch variance in cake morphology is minimized when the freezing step includes a controlled annealing hold before primary drying; failure to anneal creates heterogeneous pore structures that alter sublimation rate and can leave high-moisture domains in the lower cake layer.

Wildlife immobilization programs use the same 1:1 fixed-ratio lyophilized API in dart-delivered solutions, where the primary manufacturing concern shifts from freeze-drying control to field reconstitution and particulate management. After reconstituting a 100 mg/mL total-active solution with sterile water for injection, field teams often dilute to 50 mg/mL or 25 mg/mL using preservative-free 0.9% sodium chloride for small-bodied species requiring 1–3 mL dart volumes. The active ratio is not altered during dilution; each milliliter of a 50 mg/mL total-active solution contains 25 mg tiletamine HCl and 25 mg zolazepam HCl. Because the diluted solution has no antimicrobial preservative, it is loaded into dart cartridges immediately before the capture event and kept in insulated pouches. Field operators filter the solution through a 5 µm vented filter needle during transfer to prevent plunger binding and dart needle obstruction. In field programs, incomplete dissolution after abbreviated mixing has caused visibly turbid solution and blocked dart needles; the standard practice is to swirl without foaming until no visible cake remains and to inspect the vial against a dark background. The relevant compliance framework is not a licensed companion-animal indication; it falls under 21 CFR 530.10 extralabel use in non-food animals, FDA GFI #256 when bulk API is compounded, state wildlife agency permits, and institutional animal care and use protocols. Downstream production in this scenario is a two-stage aseptic preparation in field conditions: reconstitution of lyophilized powder followed by dilution and transfer into dart cartridges. Terminal finished product types are prefilled 1–3 mL plastic dart syringes, premixed 50 mg/mL low-volume dart solutions, and sealed sterile pouches for short-term cold transport.

Zoo Animal Chemical Restraint and the Small-Volume Syringe Accuracy Threshold

Captive exotic animal medicine requires low-concentration dilutions to avoid unacceptable dosing error when the target body mass is below 10 kg. The 100 mg/mL reconstituted stock is diluted under a laminar-flow hood with sterile 0.9% sodium chloride to 10 mg/mL total active, retaining the 1:1 tiletamine-to-zolazepam mass ratio. At this concentration, a 0.1 mL syringe with residual dead volume can generate mass error exceeding 10% for targets below 0.05 mL; compounding pharmacies and zoo hospital pharmacies therefore verify fill accuracy gravimetrically and use low-dead-volume syringes. The applicable standards include 9 CFR §2.131 for handling, 9 CFR §2.31 for institutional oversight, USP 797 for compounded sterile preparations, and the American Association of Zoo Veterinarians restraint guidelines; beyond-use dating is assigned according to sterility risk level and is normally limited to the procedure day because the diluted formulation contains no preservative. The downstream production process includes aseptic dilution, particle inspection against a black-and-white background, gravimetric fill verification, and chilled transport to the enclosure in rigid secondary containers. Terminal finished product types are pre-filled 0.3–1.0 mL Luer-lock syringes at 10 mg/mL, amber glass vials for immediate use, and disposable restraint-specific field kits containing alcohol swabs, transfer needles, and sharps containment.

Laboratory animal anesthesia protocols frequently prepare frozen aliquots of diluted tiletamine-zolazepam when rodent and rabbit procedures require rapid induction and precise dose control. The stock 100 mg/mL solution is diluted with sterile 0.9% sodium chloride to 10 mg/mL total active under a Class II biological safety cabinet; each milliliter contains 5 mg tiletamine HCl and 5 mg zolazepam HCl, maintaining the 1:1 ratio. Aliquots are filled into polypropylene cryovials and frozen at -20°C for single-use thawing at 2–8°C. Published stability data for frozen diluted tiletamine-zolazepam are limited; institutional veterinary staff therefore assign lot-specific beyond-use dates based on internal operating procedures and reject any aliquot that shows visible precipitation or pH drift after thawing. Repeated freeze-thaw cycles are not recommended because the risk of precipitation and potency loss has not been adequately characterized for preservative-free diluted preparations. The applicable framework includes 21 CFR Part 58 for nonclinical laboratory studies, the ILAR Guide for the Care and Use of Laboratory Animals 8th ed., 9 CFR §2.31 IACUC review, and USP 797 for sterile compounding. The downstream production process differs from commercial vial filling because the final container is a frozen cryovial rather than a lyophilized multi-dose vial; labeling must include storage temperature, thaw time, and institutional lot number rather than a commercial expiry. Terminal finished product types are single-use cryovials at 10 mg/mL, preloaded 0.3 mL insulin syringes drawn immediately before injection, and stock 5 mL vials stored frozen in the institutional pharmacy.

When Porcine Field Restraint Requires Multi-Dose Handling Under Ambient Conditions

Porcine chemical restraint for minor surgical or diagnostic procedures uses the reconstituted fixed-ratio injection in barn and field environments where temperature fluctuation and microbial exposure differ from companion-animal hospitals. The formulation addition ratio is unchanged: a 5 mL reconstituted vial contains 250 mg tiletamine HCl and 250 mg zolazepam HCl, producing 100 mg/mL total active. When a field protocol combines tiletamine-zolazepam with an alpha-2 agonist or ketamine, the additional drug is drawn separately because no licensed fixed-dose triple premix exists and the chemical compatibility of the mixture in a single syringe is not guaranteed without site-specific testing. The compliance pathway is 21 CFR 530.10 and 21 CFR 530.20 for extralabel use under a valid veterinarian-client-patient relationship, with bulk compounding governed by FDA GFI #256; the API remains subject to controlled-substance storage and record-keeping requirements. In field operations, multi-dose vials carried between pens are kept in insulated containers at 2–8°C, and any vial held at ambient temperature beyond the institutional beyond-use interval is discarded. Clinical experience shows prolonged recovery when pigs are placed on unheated concrete in ambient air below 15°C; thermal support and continuous observation are required until sternal recumbency is regained. The downstream production process is confined to preparation of the injectable solution, not a feed premix or oral dosage form: the lyophilized powder is reconstituted with sterile water for injection, and doses are withdrawn through sterile drawing-up devices into 2–3 mL Luer-lock syringes for intramuscular injection behind the ear. Terminal finished product types are 100 mg/mL multi-dose vials, field-chilled 3 mL Luer-lock syringes, and single-use cold-transport pouches.